Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure
Deddo Moertl
1
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
2
Department of Internal Medicine III (Cardiology), Landesklinikum St. Poelten, St. Poelten, Austria
,
Rudolf Berger
1
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
,
Alexandra Hammer
3
Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
,
Raisa Hutuleac
1
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
,
Renate Koppensteiner
3
Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
,
Christoph W. Kopp
3
Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
,
Sabine Steiner
3
Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
› InstitutsangabenFinancial support: The study was supported by the Austrian Heart Foundation
Chronic heart failure (CHF) is characterised by activation of neuroendocrine and inflammatory pathways, and both are linked to a prothrombotic state. Treatment with omega-3 polyunsaturated fatty acids (n3-PUFA) showed significant benefits including mortality reduction in CHF, but exact mechanisms of action are still unclear. We investigated the effects of n3-PUFA on markers of platelet activation and thrombogenesis in patients with severe CHF. Thirty-six patients with non-ischaemic CHF (LVEF<35%, NYHA class>2) under optimised therapy were randomised to supplementation with 1g/day or 4g/day n3-PUFA, or placebo for 12 weeks. Using whole-blood flow cytometry, monocyteplatelet aggregates characterised by CD14+/CD42b+ co-expression and monocytic tissue factor (TF) were determined. Plasma levels of P-selectin, sCD40L, fibrinogen, prothrombin fragment F1.2, TF and proinflammatory markers (high sensitive[hs] interleukin-6, hsCRP, hsTNFalpha, monocyte chemotactic protein-1) were measured by immunoassay. Supplementation with 1g/day and 4g/day n3-PUFA but not placebo significantly reduced monocyte-platelet aggregates in a dose-dependent manner (p for trend=0.02 across the groups). A dose of 4g/day but not 1g/day n3-PUFA significantly decreased P-selectin (p=0.03). Plasma TF decreased dose-dependently upon n3-PUFA supplementation (p for trend=0.02), paralleled by a significant decrease of TF+-monocytes (p for trend=0.01). The amount of 4g/day n3-PUFA exhibited modest anti-inflammatory effects with a significant reduction of hs interleukin-6 (p<0.01) and a trend-wise reduction of hsTNF-alpha (p=0.09). No changes were seen for sCD40L, fibrinogen, hsCRP and monocyte chemotactic protein-1, while F1.2 was decreased by 4g/day n3-PUFA (P=0.03). In patients with severe non-ischaemic CHF, treatment with n3-PUFA leads to a dose-dependent decrease of platelet activation and TF. Higher dosage exhibits also anti-inflammatory effects.
3
Marcucci R,
Gori AM,
Giannotti F.
et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost 2006; 4: 1017-1022.
5
Freudenberger RS,
Schumaecker MM,
Homma S.
What is the appropriate approach to prevention of thromboembolism in heart failure?. Thromb Haemost 2010; 103: 489-495.
6
Tavazzi L,
Maggioni AP,
Marchioli R.
et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223-1230.
8
Di Minno MN,
Tremoli E,
Tufano A.
et al. Exploring newer cardioprotective strategies: omega-3 fatty acids in perspective. Thromb Haemost 2010; 104: 664-680.
10
Moertl D,
Hammer A,
Steiner S.
et al. Dose-Dependent Effects of Omega-3-Poly-unsaturated Fatty Acids on Systolic Left Ventricular Function, Endothelial Function, and Markers of Inflammation in Chronic Heart Failure of Non-Ischemic Origin. Am Heart J 2011; 161: 915 e1-e9.
12
Gibbs CR,
Blann AD,
Watson RD.
et al. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001; 103: 1746-1751.
15
Chung I,
Choudhury A,
Patel J.
et al. Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure. Ann Med 2009; 41: 45-51.
16
Lee KW,
Lip GY.
Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 2003; 163: 2368-2392.
17
Din JN,
Harding SA,
Valerio CJ.
et al. Dietary intervention with oil rich fish reduces platelet-monocyte aggregation in man. Atherosclerosis 2008; 197: 290-296.
18
Tuleta I,
Bauriedel G,
Hasenbank I.
et al. Antiplatelet effects of n-3 polyunsaturated fatty acids compared with aspirin: a pilot study with whole-blood aggregometry. Thromb Res 2009; 124: 724-726.
19
Larson MK,
Ashmore JH,
Harris KA.
et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost 2008; 100: 634-641.
20
Cerbone AM,
Cirillo F,
Coppola A.
et al. Persistent impairment of platelet aggregation following cessation of a short-course dietary supplementation of moderate amounts of N-3 fatty acid ethyl esters. Thromb Haemost 1999; 82: 128-133.
21
von Schacky C,
Weber PC.
Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 1985; 76: 2446-2450.
23
Eschen O,
Christensen JH,
De Caterina R.
et al. Soluble adhesion molecules in healthy subjects: a dose-response study using n-3 fatty acids. Nutr Metab Cardiovasc Dis 2004; 14: 180-185.
24
Lee KW,
Blann AD,
Lip GY.
Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction. Thromb Res 2006; 118: 305-312.
25
Eschen O,
Christensen JH,
MT LAR.
et al. Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure. Cell Mol Biol (Noisy-le-grand) 2010; 56: 45-51.
26
Michelson AD,
Barnard MR,
Krueger LA.
et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537.
27
Lievens D,
Eijgelaar WJ,
Biessen EA.
et al. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009; 102: 206-214.
28
Stumpf C,
Lehner C,
Eskafi S.
et al. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 2003; 5: 629-637.
31
Chung I,
Choudhury A,
Patel J.
et al. Soluble CD40L, platelet surface CD40L and total platelet CD40L in congestive heart failure: relationship to platelet volume, mass and granularity. J Intern Med 2008; 263: 313-321.
32
Yan JC,
Liu PJ,
Du RZ.
et al. Relationship between CD40 ligand expression and B type natriuretic peptide levels in patients with chronic heart failure. Clin Chim Acta 2008; 392: 17-20.
33
Catellier DJ,
Aleksic N,
Folsom AR.
et al. Atherosclerosis Risk in Communities (ARIC) Carotid MRI flow cytometry study of monocyte and platelet markers: in-traindividual variability and reliability. Clin Chem 2008; 54: 1363-1371.
34
Aarsetoy H,
Brugger-Andersen T,
Hetland O.
et al. Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction. Thromb Haemost 2006; 95: 329-336.
36
Vanschoonbeek K,
Feijge MA,
Paquay M.
et al. Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vasc Biol 2004; 24: 1734-1740.
38
Del Turco S,
Basta G,
Lazzerini G.
et al. Effect of the administration of n-3 poly-unsaturated fatty acids on circulating levels of microparticles in patients with a previous myocardial infarction. Haematologica 2008; 93: 892-899.
39
Tremoli E,
Eligini S,
Colli S.
et al. n-3 fatty acid ethyl ester administration to healthy subjects and to hypertriglyceridemic patients reduces tissue factor activity in adherent monocytes. Arterioscler Thromb 1994; 14: 1600-1608.
40
Grundt H,
Hetland O,
Nilsen DW.
Changes in tissue factor and activated factor XII following an acute myocardial infarction were uninfluenced by high doses of n-3 polyunsaturated fatty acids. Thromb Haemost 2003; 89: 752-759.
41
Seljeflot I,
Hurlen M,
Arnesen H.
Increased levels of soluble tissue factor during long-term treatment with warfarin in patients after an acute myocardial infarction. J Thromb Haemost 2004; 2: 726-730.
42
Lindmark E,
Tenno T,
Siegbahn A.
Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322-2328.
